MedTrace Logo

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

NCT05218668 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-04-08

No results posted yet for this study

Summary

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Conditions

Interventions

DRUG

Fasudil (WP-0512)

Oral fasudil up to 180 mg/day

DRUG

Fasudil (WP-0512)

Oral fasudil up to 300 mg/day

Sponsors & Collaborators

  • Woolsey Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-22
Primary Completion
2026-07-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05218668 on ClinicalTrials.gov